Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs

Fig. 2

Assumed baseline survival curves for PID patients in populations with R0 values for WPV1 of 4 or 5 and assumed treatment fractions as a function of time, by income level. a Baseline survival curves, compared with reported survival for CVID patients in high-income countries [34]. b Fraction of PID patients treated with IVIG, based on literature [20, 26, 30, 31, 36, 45] and judgment

Back to article page